Welcome to our dedicated page for Theratechnologies news (Ticker: THTX), a resource for investors and traders seeking the latest updates and insights on Theratechnologies stock.
Theratechnologies Inc. was a commercial-stage biopharmaceutical company whose recent news covered product commercialization, financial results, shareholder matters and a completed acquisition. Company updates included the availability of EGRIFTA WR™ (tesamorelin) for injection, an FDA-approved formulation used to reduce excess abdominal fat in adults with HIV and lipodystrophy.
Theratechnologies news also covered quarterly operating results, regulatory and development spending categories, proxy and shareholder voting matters, capital-structure disclosures and governance matters tied to its transition following the completed acquisition by an affiliate of Future Pak.
Theratechnologies Inc. held its annual meeting of shareholders, where candidates for the Board of Directors were elected and KPMG LLP was appointed as auditors. The voting results showed high support for all candidates, with Frank Holler becoming the new Chair of the Board.
Theratechnologies will present long-term efficacy, safety, and pharmacokinetic data on the use of TH1902 in solid tumors at the 2024 ASCO Meeting. The presentation will focus on the Phase 1 clinical trial of sudocetaxel zendusortide in patients with cancers that have high SORT1 expression. Part 3 of the trial in advanced ovarian cancer is ongoing, providing valuable insights into the novel peptide-drug conjugate.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.